BioNexus Gene Lab (BGLC) Equity Average (2019 - 2026)

BioNexus Gene Lab's Equity Average history runs 8 years deep, the most recent figure standing at $8.4 million for Q1 2026.

• In Q1 2026, Equity Average rose 3.81% year-over-year to $8.4 million; the TTM figure through Mar 2026 stood at $8.4 million (up 3.81% YoY), while the FY2025 annual figure was $8.5 million, down 5.8% from the prior year.
• Equity Average came in at $8.4 million for Q1 2026 at BioNexus Gene Lab, up from $7.7 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $9.5 million in Q1 2024 to a low of $5.9 million in Q2 2023.
• A 5-year average of $7.8 million and a median of $7.6 million in 2025 frame the typical range for Equity Average.
• Across the five-year window, Equity Average soared 60.39% in 2024 and declined 24.27% in 2025, its largest moves.
• BioNexus Gene Lab's Equity Average stood at $6.5 million in 2022, then soared by 44.96% to $9.5 million in 2023, then slipped by 6.66% to $8.9 million in 2024, then declined by 12.87% to $7.7 million in 2025, then increased by 8.28% to $8.4 million in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $8.4 million, $7.7 million, and $7.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison